Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of neuroblastoma, as defined by 1 of the following:
• •* Histologically confirmed disease
• •* Bone marrow metastases plus high urine catecholamines
• •High-risk disease meeting 1 of the following stage criteria:
• •* Stage IV, with 1 of the following:
• •* Any age with MYCN amplification
• •* \> 18 months of age without MYCN amplification
• •* Stage III, with both of the following:
• •* Any age with MYCN amplification
• •* Unresectable disease
• •* Stage 4S with MYCN amplification
• •Measurable or evaluable soft tissue disease
• •Relapsed disease resistant to standard induction chemotherapy and salvage therapy
• •PATIENT CHARACTERISTICS:
• •Age
• •Any age
• •Performance status
• •Not specified
• •Life expectancy
• •Not specified
• •Hematopoietic
• •Not specified
• •Hepatic
• •No severe hepatic toxicity ≥ grade 3
• •Renal
• •No severe renal toxicity ≥ grade 3
• •Cardiovascular
• •No severe cardiac toxicity ≥ grade 3
• •Pulmonary
• •No severe pulmonary toxicity ≥ grade 3
• •Other
• •Not pregnant
• •Negative pregnancy test
• •No severe neurologic toxicity ≥ grade 3
• •No severe gastrointestinal toxicity ≥ grade 3
• •No other severe major organ dysfunction except ototoxicity
• •No history of allergy to mouse proteins
• •No active life-threatening infection
• •No human anti-mouse antibody titer \> 1,000 ELISA units/mL
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •See Disease Characteristics
• •Endocrine therapy
• •Not specified
• •Radiotherapy
• •Not specified
• •Surgery
• •Not specified